AZD6234 + AZD9550

**AZD6234 + AZD9550** is a combination investigational therapy under development by AstraZeneca for the treatment of obesity and overweight, including patients with co-morbidities such as non-alcoholic steatohepatitis (NASH) and Type 2 Diabetes. The combination is administered as once-weekly subcutaneous injections and is being evaluated for its efficacy, safety, and tolerability versus placebo and single-agent therapy. AZD9550 acts as a dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R), aiming to induce weight loss, improve metabolic health, and reduce hepatic fat. AZD6234 targets the amylin pathway, which may promote fat-selective weight reduction and is considered an alternative for those intolerant to incretin therapies. Their co-administration seeks a synergistic effect on weight loss and metabolic outcomes, with potential organ protective benefits[1][4][5][7].

Other names

AZD9550 and AZD6234AZD-9550 and AZD6234AZD 9550 and AZD6234